Theator Achieves HITRUST CSF® Certification for Ensuring the Highest Standards of Privacy and Compliance to Partner Healthcare Institutions

Theator, the creator of Surgical Intelligence, announced today that it has achieved the HITRUST Cyber Security Framework (CSF) certification for practicing security protocols that meet both risk- and compliance-based HITRUST CSF requirements.

HITRUST CSF is a certifiable framework that provides organizations with a comprehensive, flexible, and efficient approach to regulatory compliance and risk management. Due to the sensitive nature of healthcare data specifically and the rise in healthcare breaches this year, HITRUST CSF certification is essential for health technology vendors to instill confidence in security measures and protect the very patients they aim to help. This accomplishment demonstrates the high level of importance Theator places on privacy, security, and compliance and solidifies Theator as a leader in all three areas. With HITRUST CSF certification, Theator is committed to maintaining the highest levels of nationally and internationally accepted security and privacy-related regulatory adherence in ongoing and future projects.

“Surgical Intelligence increases visibility into the OR to better evaluate surgical best practices, so we, at Theator, have a responsibility to provide our partners and their patients with the highest levels of protection,” said Dotan Asselmann, CTO and Co-founder of Theator. “HITRUST CSF certification instills that confidence in Theator’s technology and accelerates our mission to define a new gold standard in surgical care.”

Theator created the category of Surgical Intelligence to increase OR visibility and eliminate the widespread variability and disparity plaguing the surgical field. Theator’s first-of-its-kind Surgical Intelligence Platform institutionalizes automatic and routine surgical video capture, layering footage with AI-powered analysis of every operation. Surgical stakeholders access actionable insights to deliver optimized patient outcomes, ultimately enhancing surgical best practices and raising overall standards of care.

Most recently, in July 2022, Theator announced it had closed out its Series A funding with $39.5M, having now raised a total of $42.5M. In the last year, Theator has collaborated with Mayo Clinic and partnered with the Canadian Association of General Surgeons (CAGS), adding further prestige to the burgeoning list of innovative medical institutions and surgical societies adopting Surgical Intelligence. Last December, the company was named on CB Insights’ prestigious Digital Health 150 list of the 150 most innovative digital health startups in the world, highlighting industry recognition of Surgical Intelligence as a distinct category for the first time.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.
“These study results are highly encouraging especially given the short treatment duration of 10 days with BX004,” said Jonathan Solomon, Chief Executive Officer of BiomX. “In Part 2 of the study, BX004 showed clinically meaningful improvement in pulmonary function compared to placebo, as measured by relative FEV11 improvement (5.67% at Day 17, 1 week after end of treatment) and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain (8.87 points at Day 17) in a predefined subgroup of patients with reduced lung function.”  
Importantly, the study reported no serious treatment-related adverse events from any of the 109 patients treated with InGeneron’s Transpose® RT cell therapy system.

By using this website you agree to accept Medical Device News Magazine Privacy Policy